HIMSS Analytics launches market intelligence tool

HIMSS Analytics has launched Logic, a global healthcare IT market intelligence tool.

The tool was collaboratively built with hospitals and health systems and allows healthcare providers, healthcare IT companies, governmental and education organizations along with investors to gain crucial insights for guiding healthcare IT strategies, according to the organization.  

Logic will provide insight into predictive modeling, benchmarks and value optimization of health IT, including ranking and adoption of the HIMSS Analytics Electronic Medical Record Adoption Model (EMRAM). Logic builds off the current HIMSS Analytics Database, which stores key data insights from provider institutions across the country. New features include more visualizations and customizable dashboards that generate actionable market intelligence on-demand, such as usage, first-time purchases, upgrades or replacements and key healthcare decisions makers.

“Our customers have come to rely on us for the most cutting edge, reliable insights and data. Now, with Logic, the industry can access actionable data faster than any other resource in the market,” said Blain Newton, HIMSS Analytics COO, in a release. “Logic is also unique in that it offers benefits for organizations both large and small--tech giants and emerging companies alike can leverage Logic to improve their understanding of the marketplace.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.